Yahoo
OTC Markets OTCPK - Delayed Quote USD

Sernova Biotherapeutics Inc (SEOVF)

0.0800 0.0000 (0.00%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for SEOVF
  • Previous Close 0.0800
  • Open 0.0759
  • Bid 0.0712 x 6000000
  • Ask 0.0756 x 1500000
  • Day's Range 0.0759 - 0.0759
  • 52 Week Range 0.0600 - 0.1400
  • Volume 458
  • Avg. Volume 84,592
  • Market Cap (intraday) 30.211M
  • Beta (5Y Monthly) 0.64
  • PE Ratio (TTM) 8.00
  • EPS (TTM) 0.0100
  • Earnings Date (est.) Dec 17, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada.

www.sernova.com

8

Full Time Employees

October 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

SEOVF
11.11%
S&P/TSX Composite index (^GSPTSE)
11.78%

1-Year Return

SEOVF
27.27%
S&P/TSX Composite index (^GSPTSE)
18.03%

3-Year Return

SEOVF
85.96%
S&P/TSX Composite index (^GSPTSE)
88.90%

5-Year Return

SEOVF
91.92%
S&P/TSX Composite index (^GSPTSE)
69.32%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue --
Earnings -2.53M
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-3M
-2M
-1M
0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -868.43%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -10.29M

  • Diluted EPS (ttm)

    0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    63.33k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -14.83M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: